Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof

a technology of empagliflozin and cocrystals, applied in the field of process for the preparation of empagliflozin or its cocrystals, solvates and/or polymorphs thereof, can solve the problems of high cost, difficult large-scale implementation, and insatiable purity of the empagliflozin obtained from the above process

Active Publication Date: 2020-04-30
LAURUS LABS
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The technical effect of this patented method is that it reduces the amount of certain chemicals called Formula Vb or VIII in an organic substance by converting them into another type of molecule called Compound IIIa. This new form can be used for various applications such as medicine or other purposes.

Problems solved by technology

This patent describes various methods for making it possible to reduce the amount of time needed for achieving desired levels of Compound 1 in the Intermediate Chemistry Complex (ICC). These techniques involve separating the necessary chemical components beforehand, reducing costs while maintaining quality standards.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof
  • Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof
  • Novel process for preparation of empagliflozin or its co-crystals, solvates and their polymorphs thereof

Examples

Experimental program
Comparison scheme
Effect test

example 5

on of Compound of Formula III

[0289]The residue of compound of Formula IV was dissolved in a mixture of acetonitrile (300 ml) and dichloromethane (300 ml) at 25-35° C. Triethylsilane (129.2 gr) was added at 25-35° C. and the temperature of the reaction mass was cooled to −25 to −35° C. Borontrifluoride-diethyletherate (158.1 gr) was added to the reaction mass at −40 to −30° C. and stirred for 15 to 20 min. Temperature of the reaction mass was raised to 0° C. and further maintained with stirring for 3 to 4 hrs. Water was added, and the layers were separated and the aqueous layer was extracted with 2-methyltetrahydrofuran or ethyl acetate, combined the organic layers and washed with water, 8% sodium bicarbonate solution and further with 10% brine solution and dried over sodium sulphate. The organic layer was distilled completely under vacuum at below 45° C. and co-distilled with n-heptane and purified by ethyl acetate to obtain the title compound as a solid.

Yield: 40 gms

example 6

on of Empagliflozin of Formula I

[0290]The residue of compound of Formula III was dissolved in N,N-Dimethylformamide (210 ml) at 25-35° C. Cesium carbonate (74.5 gr) and R-Tosyl tetrahydrofuran (26.8 gr) was added. Raised the temperature of the reaction mass to 45° C. to 50° C. and maintained for 12-24 hrs. Water and dichloromethane (525 ml) were added to the reaction mass and adjust the pH of the reaction mass to 7.0 to 8.0 using 5% hydrochloric acid solution. Separate the layers and extract the aqueous layer with dichloromethane. Organic layers were combined and washed with water, 10% sodium chloride, and dried over sodium sulphate. Filtered the solid and dried over vacuum to obtain empagliflozin as a residue.

Example 7: Preparation of Empagliflozin

[0291]The residue of compound of Formula III was dissolved in dimethylsulphoxide (210 ml) at 25-35° C. Cesium carbonate (74.5 gr) and R-Tosyl tetrahydrofuran (26.8 gr) was added. Raised the temperature of the reaction mass to 45° C. to 50° C

example 7

on of Empagliflozin-DL-Pipecolic Acid

[0292]The residue of empagliflozin, obtained according to Example 5 was added to DL-pipecolic acid (24 gr) and water (21 mL) at 80-85° C. and stirred the reaction mass for about 1 hr at 80-85° C. The reaction mass was allowed to cool to 25-35° C. and stirred for 24-48 hrs. Filtered the reaction mass and washed with n-butanol and dried the product at 45-50° C. under vacuum for 6-8 hrs.

Yield: 50 gms. HPLC: NLT 99.0%

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Temperatureaaaaaaaaaa
Login to view more

Abstract

The present invention relates to process for the preparation of Empagliflozin or its co-crystals, solvates and/or polymorphs thereof. The present invention also relates to novel intermediates used therein, and process for the preparation thereof. The present invention further relates to process for preparation of amorphous and crystalline form of Empagliflozin.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner LAURUS LABS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products